603 related articles for article (PubMed ID: 28250116)
1. A Neonatal Murine Model of Coxsackievirus A6 Infection for Evaluation of Antiviral and Vaccine Efficacy.
Zhang Z; Dong Z; Wei Q; Carr MJ; Li J; Ding S; Tong Y; Li D; Shi W
J Virol; 2017 May; 91(9):. PubMed ID: 28250116
[TBL] [Abstract][Full Text] [Related]
2. A 10-Day-Old Murine Model of Coxsackievirus A6 Infection for the Evaluation of Vaccines and Antiviral Drugs.
Jiang Z; Zhang Y; Lin H; Cheng Q; Lu X; Liu W; Zhou R; Zhong B; Tian X
Front Immunol; 2021; 12():665197. PubMed ID: 34054834
[TBL] [Abstract][Full Text] [Related]
3. Protective Efficacies of Formaldehyde-Inactivated Whole-Virus Vaccine and Antivirals in a Murine Model of Coxsackievirus A10 Infection.
Zhang Z; Dong Z; Li J; Carr MJ; Zhuang D; Wang J; Zhang Y; Ding S; Tong Y; Li D; Shi W
J Virol; 2017 Jul; 91(13):. PubMed ID: 28424287
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of a Trivalent Hand, Foot, and Mouth Disease Vaccine against Enterovirus 71 and Coxsackieviruses A16 and A6 in Mice.
Caine EA; Fuchs J; Das SC; Partidos CD; Osorio JE
Viruses; 2015 Nov; 7(11):5919-32. PubMed ID: 26593938
[TBL] [Abstract][Full Text] [Related]
5. A neonatal murine model of coxsackievirus A4 infection for evaluation of vaccines and antiviral drugs.
Zhang Z; Zhang X; Carr MJ; Zhou H; Li J; Liu S; Liu T; Xing W; Shi W
Emerg Microbes Infect; 2019; 8(1):1445-1455. PubMed ID: 31595827
[TBL] [Abstract][Full Text] [Related]
6. Characterization of an inactivated whole-virus bivalent vaccine that induces balanced protective immunity against coxsackievirus A6 and A10 in mice.
Zhang Z; Dong Z; Wang Q; Carr MJ; Li J; Liu T; Li D; Shi W
Vaccine; 2018 Nov; 36(46):7095-7104. PubMed ID: 30316529
[TBL] [Abstract][Full Text] [Related]
7. A virus-like particle-based tetravalent vaccine for hand, foot, and mouth disease elicits broad and balanced protective immunity.
Zhang W; Dai W; Zhang C; Zhou Y; Xiong P; Wang S; Ye X; Liu Q; Zhou D; Huang Z
Emerg Microbes Infect; 2018 May; 7(1):94. PubMed ID: 29777102
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of monovalent and bivalent vaccines against lethal Enterovirus 71 and Coxsackievirus A16 infection in newborn mice.
Sun S; Jiang L; Liang Z; Mao Q; Su W; Zhang H; Li X; Jin J; Xu L; Zhao D; Fan P; An D; Yang P; Lu J; Lv X; Sun B; Xu F; Kong W; Jiang C
Hum Vaccin Immunother; 2014; 10(10):2885-95. PubMed ID: 25483672
[TBL] [Abstract][Full Text] [Related]
9. Immunological and biochemical characterizations of coxsackievirus A6 and A10 viral particles.
Liu CC; Guo MS; Wu SR; Lin HY; Yang YT; Liu WC; Chow YH; Shieh DB; Wang JR; Chong P
Antiviral Res; 2016 May; 129():58-66. PubMed ID: 26899790
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of a coxsackievirus A6 vaccine candidate in an actively immunized mouse model.
Qian SS; Wei ZN; Jin WP; Wu J; Zhou YP; Meng SL; Guo J; Wang ZJ; Shen S
Emerg Microbes Infect; 2021 Dec; 10(1):763-773. PubMed ID: 33739899
[TBL] [Abstract][Full Text] [Related]
11. The immunogenicity and protection effect of an inactivated coxsackievirus A6, A10, and A16 vaccine against hand, foot, and mouth disease.
Lim H; In HJ; Lee JA; Sik Yoo J; Lee SW; Chung GT; Choi YK; Chung JK; Cho SJ; Lee JW
Vaccine; 2018 Jun; 36(24):3445-3452. PubMed ID: 29739716
[TBL] [Abstract][Full Text] [Related]
12. Coxsackievirus A6 Infection Causes Neurogenic Pathogenesis in a Neonatal Murine Model.
Sun Q; Li J; Wang R; Sun T; Zong Y; Wang C; Liu Y; Li X; Song Y; Zhang Y
Viruses; 2023 Feb; 15(2):. PubMed ID: 36851724
[TBL] [Abstract][Full Text] [Related]
13. Recent development of enterovirus A vaccine candidates for the prevention of hand, foot, and mouth disease.
Fang CY; Liu CC
Expert Rev Vaccines; 2018 Sep; 17(9):819-831. PubMed ID: 30095317
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of Coxsackievirus A5 Vaccine Candidates in an Actively Immunized Mouse Model.
Jin WP; Lu J; Zhang XY; Wu J; Wei ZN; Mai JY; Qian SS; Yu YT; Meng SL; Wang ZJ; Shen S
J Virol; 2021 Feb; 95(6):. PubMed ID: 33408178
[TBL] [Abstract][Full Text] [Related]
15. A neonatal mouse model for the evaluation of antibodies and vaccines against coxsackievirus A6.
Yang L; Mao Q; Li S; Gao F; Zhao H; Liu Y; Wan J; Ye X; Xia N; Cheng T; Liang Z
Antiviral Res; 2016 Oct; 134():50-57. PubMed ID: 27582066
[TBL] [Abstract][Full Text] [Related]
16. Clinically isolated enterovirus A71 subgenogroup C4 strain with lethal pathogenicity in 14-day-old mice and the application as an EV-A71 mouse infection model.
Xu Y; Ma S; Zhu L; Huang Z; Chen L; Xu Y; Yin H; Peng T; Wang Y
Antiviral Res; 2017 Jan; 137():67-75. PubMed ID: 27864074
[TBL] [Abstract][Full Text] [Related]
17. A mouse-adapted CVA6 strain exhibits neurotropism and triggers systemic manifestations in a novel murine model.
Li D; Sun T; Tao L; Ji W; Zhu P; Liang R; Zhang Y; Chen S; Yang H; Jin Y; Duan G
Emerg Microbes Infect; 2022 Dec; 11(1):2248-2263. PubMed ID: 36036059
[TBL] [Abstract][Full Text] [Related]
18. A murine model of coxsackievirus A16 infection for anti-viral evaluation.
Liu Q; Shi J; Huang X; Liu F; Cai Y; Lan K; Huang Z
Antiviral Res; 2014 May; 105():26-31. PubMed ID: 24583030
[TBL] [Abstract][Full Text] [Related]
19. Novel recombinant chimeric virus-like particle is immunogenic and protective against both enterovirus 71 and coxsackievirus A16 in mice.
Zhao H; Li HY; Han JF; Deng YQ; Zhu SY; Li XF; Yang HQ; Li YX; Zhang Y; Qin ED; Chen R; Qin CF
Sci Rep; 2015 Jan; 5():7878. PubMed ID: 25597595
[TBL] [Abstract][Full Text] [Related]
20. A Mouse Model of Enterovirus D68 Infection for Assessment of the Efficacy of Inactivated Vaccine.
Zhang C; Zhang X; Dai W; Liu Q; Xiong P; Wang S; Geng L; Gong S; Huang Z
Viruses; 2018 Jan; 10(2):. PubMed ID: 29385753
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
